Inflammation: Rituximab in ANCA vasculitis and lupus: bittersweet results.
Bosch
Xavier
X
D019268:Antibodies, Antineutrophil Cytoplasmic / Q000276:immunology* / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D008181:Lupus Nephritis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D008212:Lymphocyte Depletion; D008297:Male; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012016:Reference Values; D018570:Risk Assessment; D000069283:Rituximab; D012720:Severity of Illness Index; D017211:Treatment Failure; D014657:Vasculitis / Q000188:drug therapy* / Q000276:immunology
D019268:Antibodies, Antineutrophil Cytoplasmic; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab